- Home
- HRMY vs SAH Comparison
HRMY vs SAH Comparison
Compare HRMY & SAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SAH
- Stock Information
- Founded
- HRMY 2017
- SAH 1997
- Country
- HRMY United States
- SAH United States
- Employees
- HRMY N/A
- SAH N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SAH Other Specialty Stores
- Sector
- HRMY Health Care
- SAH Consumer Discretionary
- Exchange
- HRMY Nasdaq
- SAH Nasdaq
- Market Cap
- HRMY 1.5B
- SAH 2.8B
- IPO Year
- HRMY 2020
- SAH 1997
- Fundamental
- Price
- HRMY $29.70
- SAH $65.52
- Analyst Decision
- HRMY Strong Buy
- SAH Buy
- Analyst Count
- HRMY 10
- SAH 8
- Target Price
- HRMY $50.80
- SAH $82.50
- AVG Volume (30 Days)
- HRMY 866.3K
- SAH 163.2K
- Earning Date
- HRMY 11-04-2025
- SAH 10-23-2025
- Dividend Yield
- HRMY N/A
- SAH 2.32%
- EPS Growth
- HRMY 58.41
- SAH N/A
- EPS
- HRMY 3.10
- SAH 3.73
- Revenue
- HRMY $772,527,000.00
- SAH $15,178,100,000.00
- Revenue This Year
- HRMY $20.10
- SAH $4.86
- Revenue Next Year
- HRMY $16.50
- SAH $3.51
- P/E Ratio
- HRMY $9.56
- SAH $17.54
- Revenue Growth
- HRMY 17.74
- SAH 9.09
- 52 Week Low
- HRMY $25.52
- SAH $52.00
- 52 Week High
- HRMY $41.61
- SAH $89.62
- Technical
- Relative Strength Index (RSI)
- HRMY 57.50
- SAH 29.61
- Support Level
- HRMY $25.52
- SAH $70.70
- Resistance Level
- HRMY $26.97
- SAH $77.85
- Average True Range (ATR)
- HRMY 0.87
- SAH 2.74
- MACD
- HRMY 0.63
- SAH -0.58
- Stochastic Oscillator
- HRMY 84.81
- SAH 4.45
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SAH Sonic Automotive Inc.
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.